2024.01.16
About HoneyBear
HoneyBear Biosciences, Inc is a Taiwan based biotech company with a vision for global pharmaceutical market. We strive to develop new antibody technologies to bring novel antibody-drug conjugates.
HoneyBear licensed the site-specific dual-payload glycan conjugation platform from Development Center for Biotechnology (DCB) and are focusing on taking this strongly competitive platform to the clinical stage.
Unique site-specific dual-payload glycan conjugation platform
Antibody-drug conjugates (ADCs) are a class of therapeutics, in which the drugs can be attached to the antibody through specific linkers and conjugation methods.
IP Protection of Glycan Conjugation
Pipeline
Honeybear is translating the novel site-specific glycan conjugation platform into breakthrough medicines.
